Fulcrum announces Phase 3 trial of losmapimod
From Fulcrum Therapeutics’ press release Reachable Workspace (RWS) primary endpoint based on discussions with FDA and EU regulatory agencies Trial expected to begin in 2Q 2022 Potential first-to-market therapy for […]